hyaluronidase 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
enzymes 5033 9001-54-1

Description:

MoleculeDescription

Synonyms:

  • hyaluronidase recombinant human
  • hyaluronidase
  • wydase
  • hyaluronidase ovine
  • hyaluronidase bovine
  • vorhyaluronidase alfa (genetical recombination)
An enzyme that catalyzes the random hydrolysis of 1,4-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate. (From Enzyme Nomenclature, 1992) There has been use as ANTINEOPLASTIC AGENTS to limit NEOPLASM METASTASIS.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
March 22, 1950 FDA BAXTER HLTHCARE
Aug. 25, 2021 PMDA Janssen Pharmaceutical, K.K.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Parophthalmia 96.78 28.11 16 2726 307 63485973
Purtscher retinopathy 91.42 28.11 13 2729 85 63486195
Conjunctival oedema 71.96 28.11 14 2728 688 63485592
Exophthalmos 55.88 28.11 13 2729 1503 63484777
Product administered at inappropriate site 55.72 28.11 15 2727 3134 63483146
Lagophthalmos 48.03 28.11 9 2733 361 63485919
Blood phosphorus increased 46.46 28.11 13 2729 3132 63483148
Protein total decreased 38.24 28.11 13 2729 5964 63480316
Deep vein thrombosis postoperative 36.82 28.11 15 2727 11354 63474926
Hypernatraemia 35.17 28.11 13 2729 7596 63478684
Sensory loss 34.85 28.11 14 2728 10224 63476056
Rectal haemorrhage 34.06 28.11 23 2719 49007 63437273
Autoimmune disorder 30.88 28.11 15 2727 17162 63469118

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Parophthalmia 95.71 29.01 16 2980 381 79741011
Purtscher retinopathy 89.97 29.01 13 2983 113 79741279
Lagophthalmos 87.11 29.01 15 2981 428 79740964
Product administered at inappropriate site 59.02 29.01 16 2980 3949 79737443
Exophthalmos 55.97 29.01 13 2983 1717 79739675
Conjunctival oedema 55.51 29.01 12 2984 1146 79740246
Strabismus 46.22 29.01 12 2984 2509 79738883
Deep vein thrombosis postoperative 39.66 29.01 15 2981 10737 79730655
Cellulitis orbital 36.72 29.01 8 2988 791 79740601
Protein total decreased 34.68 29.01 13 2983 9079 79732313
Sensory loss 33.51 29.01 14 2982 12977 79728415
Autoimmune disorder 33.35 29.01 15 2981 16597 79724795
Blood phosphorus increased 33.04 29.01 13 2983 10334 79731058
Retinal artery occlusion 29.72 29.01 9 2987 3285 79738107

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B06AA03 BLOOD AND BLOOD FORMING ORGANS
OTHER HEMATOLOGICAL AGENTS
OTHER HEMATOLOGICAL AGENTS
Enzymes
FDA CS M0009499 Glycoside Hydrolases
FDA EPC N0000175531 Endoglycosidase

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Systemic AL amyloidosis indication 23132008
Multiple myeloma indication 109989006 DOID:9538
Subcutaneous clysis of patient for fluid administration indication 113154008




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D04456 KEGG_DRUG
4018028 VUID
N0000146371 NUI
4018028 VANDF
C0020197 UMLSCUI
CHEMBL1201636 ChEMBL_ID
91820602 PUBCHEM_CID
DB14740 DRUGBANK_ID
CHEMBL1201718 ChEMBL_ID
CHEMBL2108607 ChEMBL_ID
DB06205 DRUGBANK_ID
1300478 RXNORM
1312 MMSL
4832 MMSL
63625 MMSL
d01393 MMSL
001887 NDDF
010831 NDDF
011274 NDDF
387280008 SNOMEDCT_US
420670008 SNOMEDCT_US
420993004 SNOMEDCT_US
51132001 SNOMEDCT_US
784400007 SNOMEDCT_US
786123000 SNOMEDCT_US
D006821 MESH_DESCRIPTOR_UI

Pharmaceutical products:

None